New gene therapy trial hopes to slow Friedreich's ataxia

NCT ID NCT07180355

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 27 times

Summary

This early-stage trial tests a new gene therapy called SGT-212 in 10 adults with Friedreich's ataxia, a rare genetic disease that affects movement and coordination. The treatment is given through an injection into the brain and a vein. The main goal is to see if it is safe and tolerable over about 5 years.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FRIEDREICH'S ATAXIA (FA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The Children's Hospital of Philadelphia (CHOP)

    NOT_YET_RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

  • The Ohio State University

    RECRUITING

    Columbus, Ohio, 43210, United States

    Contact Email: •••••@•••••

    Contact

  • The University of California, Los Angeles (UCLA)

    NOT_YET_RECRUITING

    Los Angeles, California, 90095, United States

    Contact Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.